AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Thyme Care, founded in 2020, has expanded its cancer care services to over 3000 patients by 2023, achieving a $594 cost reduction per patient per month. With a $95 million funding round in 2024, the company aims to further reduce pharmacy waste and administrative burdens through data analytics, improve referral processes among oncology and primary care, and integrate deeply into partner practices to find efficiencies. Thyme Care's model, which assumes two-sided risk, focuses on enhancing patient experience, quality, and waste reduction, attracting investors like Concord Health Partners. The company plans to tackle drug spend collaboratively with oncologists and improve value-based care arrangements, with a focus on early palliative care and supportive services.

New research finds dark-skinned cancer patients have higher risk of severe reactions to radiation therapy, with a need for improved screening tools to detect radiation dermatitis.

CEL-SCI Corporation plans to offer up to $150M of common, preferred, convertible preferred stock, rights, warrants, and units. The securities will be sold at prices and terms determined at or prior to the time of sale, considering market conditions. The offering includes reoffering shares held by certain shareholders. Specific terms will be detailed in accompanying prospectus supplements. CEL-SCI may sell securities directly, through agents, or underwriters. The securities are speculative and involve high risk, suitable only for those who can afford to lose their investment. CEL-SCI's common stock trades on the NYSE American under the symbol 'CVM'.

Emerging combination regimens for metastatic colorectal cancer (mCRC) post-frontline therapy include TKIs, EGFR and VEGF inhibitors, emphasizing molecular testing for personalized second and third-line treatments. Key trials like CodeBreaK300 and MOUNTAINEER support novel agents like sotorasib and tucatinib plus trastuzumab. Third-line options such as regorafenib, trifluridine/tipiracil with or without bevacizumab, and fruquintinib expand treatment choices, with studies like SUNLIGHT and FRESCO series highlighting their efficacy and safety.

Hispanic and Latino people make up 20% of the U.S. population but only 6% of physicians. A panel discussion highlighted the need for more Latino physicians, the importance of trust and language concordance in clinical trials, and the diverse backgrounds within the Latino community. Efforts to educate and support Latino clinicians and researchers are crucial for health equity.

Experts discuss the use of sacituzumab govitecan and trastuzumab deruxtecan in breast cancer treatment, focusing on safety profiles, supportive care, and therapeutic sequencing. They highlight the importance of G-CSF use, the modest overall survival improvement with sacituzumab, and the better tolerability of trastuzumab deruxtecan. The discussion also covers the management of treatment-related toxicities, particularly neutropenia and diarrhea, and the need for early intervention with steroids to mitigate adverse effects.

The FDA approved inavolisib, palbociclib, and fulvestrant for HR+, HER2–, PIK3CA-mutated breast cancer, supported by the phase 3 INAVO120 study. Inavolisib reduced progression risk by 57% and improved progression-free survival to 15.0 months vs 7.3 months with placebo.

ASCO 2024 showcased precision cancer medicine's clinical relevance, with molecularly targeted therapies becoming standard of care in multiple cancer types. Notably, lorlatinib demonstrated superior 5-year progression-free survival in ALK-positive NSCLC compared to crizotinib. Precision medicine also expanded to hematologic malignancies, with asciminib showing higher efficacy and reduced toxicity in chronic myelocytic leukemia. The paradigm highlights the rationality of antineoplastic drug development, emphasizing continuous improvement and substitution of more effective regimens.

AbbVie submitted a BLA to the FDA for telisotuzumab vedotin (Teliso-V) in metastatic EGFR wild-type nonsquamous NSCLC with c-Met overexpression. Data from the phase 2 LUMINOSITY trial showed ORR of 34.6%, 22.9%, and 28.6% in high, intermediate, and overall c-Met overexpression groups, respectively. Median DOR was 9.0, 7.2, and 8.3 months, and median PFS was 5.5, 6.0, and 5.7 months. No new safety signals were observed.